We inferred that ATM mutation is likely to improve the prognosis of bladder cancer patients by downregulating the activity of the insulin-like growth factor receptor pathway and ATM-MT bladder cancer patients may benefit from the combined application of ICIs and IGF-1R inhibitors, which opens a new approach for clinical treatment (Figure 7). This evidence concerns the gene IGF1R and urinary bladder cancer.